Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2007-06-19
2007-06-19
Nashed, Nashaat T. (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S814000, C514S008100, C530S350000
Reexamination Certificate
active
10304382
ABSTRACT:
The present invention provides a new subcutaneous injection dosing regimen for erythropoietin to treat anemia. The new erythropoietin treatment regimen of the present invention results in improved hemoglobin levels with less frequent dosing.
REFERENCES:
patent: 5643575 (1997-07-01), Martinez et al.
patent: 5688679 (1997-11-01), Powell
patent: 0 640 619 (1995-03-01), None
patent: WO 94/12650 (1994-06-01), None
patent: WO 98/05363 (1998-02-01), None
patent: WO 99/05268 (1999-02-01), None
patent: WO 99/11781 (1999-03-01), None
patent: WO 99/38890 (1999-08-01), None
patent: WO 99/66054 (1999-12-01), None
patent: WO 00/67776 (2000-11-01), None
Farrell et al. Administration of epoetin alfa every two weeks is able to sustain target hemoglobin in a nonhuman primate alternate dosing model. Nov. 16, 2001, Blood, vol. 98, No. 11, Part 1, pp. 297a).
Piccoli et al. A Decision Analysis Comparing Three Dosage Regimens of Subcutaneous Epoetin in Continous Ambulatory Peritoneal Dialysis. 1995, PharmacoEconomics, vol. 7, No. 5, pp. 444-456.
Nomoto et al. A Multicenter Study with Once a Week or Once Every Two Weeks High-Dose Subcutaneous Administration of Recombinant Human Erythyropoietin in Continuous Ambulatory Peritoneal Dialysis, 1994, Pert. Dial. Int. vol. 14, pp. 56-60.
Weiss, Lars. Flexible dosing schemes for recombinant human erythropoietin—Lessons from our daily practice. Jul. 2001, Nephrol. Dial. Transplant. 16 [Supp. 7], pp. 15-19.
Piccoli et al. Subcutaneous epoetin-alpha every one, two, and three weeks in renal anemia. 2002, J. Nephrol. vol. 15, No. 5, p. 565-574.
Wognum, A.W. Mini-Review: Erythropoietin, Stemcell Technologies, pp. 1-4, 29013, Version 1.0.0, found at www.stemcell.com/technical/29013—epo.pdf.
Lundin, A.P., et al., “Exercise in hemodialysis patients after treatment with recombinant human erythropoietin,”Nephron, 1991, 58, 315-319.
Silverberg, D.S., et al., “The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations,”J. of the American College of Cardiology, 2000, 35(7), 1737-1744.
Breymann C, et al. “Optimal Timing of Repeated Rh-erythropoietin Administration Improves its Effectiveness in Stimulating Erythropoiesis in Healthy Volunteers”,Brit J Heamatol. 1996, 92:295-301.
Egrie JC., “Characterization and Biological Effects of Recombinant Human Erythropoietin”,Immunobiology, 1986, 172, 213-224.
Faulds D., “Epoetin (Recombinant Human Erythropoietin): A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Potential in Anemia and the Stimulation of Erythropoiesis”,Drugs, 1989, 38:863-899.
Jacobs K., et al. “Isolation and Characterization of Genomic and cDNA Clones of Human Erythropoietin”,Nature, 1985, 313:806-810.
Jelkmann W., “Erythropoietin: Structure, Control of Production, and Function”,Physiol Rev, 1992, 72(2), 449-489.
Koury ST,. et al., “Localization of Erythropoietin Synthesizing Cells in Murine Kidneys by in Situ Hybridization”,Blood, 1988, 71(2), 524-527.
Lin FK, et al., Cloning and Expression of the Human Erythropoietin Gene.Proc Natl Acad Sci, USA, 1985 82:7580-7584.
Markham A, Bryson HM., “Epoetin Alfa: A Review of its Pharmacodynamic and Pharmacokinetic Properties and Therapeutic Use in Nonrenal Applications”,Drugs, 1995 49(2), 232-254.
Farrell Francis
Jolliffe Linda K.
Nashed Nashaat T.
Ortho-McNeil Pharmaceutical , Inc.
Ren Yunling
Schnizer Holly G.
LandOfFree
Erythropoietin dosing regimen for treating anemia does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Erythropoietin dosing regimen for treating anemia, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin dosing regimen for treating anemia will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3835446